靶向EGFR治疗联合化疗与单纯化疗对口腔癌痛的影响

Effect of EGFR-targeted therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain

目的:比较靶向表皮生长因子受体(epidermal growth factor receptor,EGFR)治疗联合化疗与单纯化疗对口腔癌痛的影响。方法:选择患有慢性癌痛的口腔癌患者90例,根据接受治疗的方式分为单纯化疗组(G0组)和靶向EGFR治疗联合化疗组(G1组)。在患者入院(T0)、治疗后第1天(T1)、第7天(T2)和第3个月末(T3),使用视觉模拟评分(VAS)和数字疼痛评分表(NRS)评估疼痛强度。在T0和T3,使用自评利兹神经病理性疼痛症状与体征评价量表(SLANSS)评价患者神经病理性疼痛,记录辅助镇痛药物的使用和睡眠时长;在T3时记录治疗副作用和满意度。采用SPSS 26.0软件包对数据进行统计学分析。结果:G0组和G1组分别纳入31例和59例患者。受试者平均年龄60.64岁,70%为男性。2组患者T0时的VAS和NRS无显著差异,而G1组在T1、T2和T3时的VAS和NRS较G0组显著降低(P<0.05)。G1组较G0组在T3时使用的镇痛药物显著减少(P<0.05),睡眠时间显著延长(P<0.05),满意度更高(P<0.05)。结论:靶向EGFR治疗联合化疗相比单纯化疗对口腔癌痛的缓解作用更明显,可减少辅助镇痛药物的使用。

PURPOSE:To compare the effect of epidermal growth factor receptor-targete(dEGFR-targeted)therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain.METHODS:Ninety oral cancer patients with chronic cancer pain were divided into chemotherapy alone group(group GO)and EGFR-targeted therapy combined with chemotherapy group(group Gl)according to the type of treatment they received.Pain intensity was assessed at baseline(TO),day 1(T1),day 7(T2)and at the end of month 3(T3)using visual analogue scale(VAS)and numerical rating scale for pain(NRS).The patients were assessed for neuropathic pain using self-administrative Leeds neuropathic pain signs and symptoms scale(S-LANSS),and adjunctive analgesic use,sleep duration were recorded at TO and T3.Treatment side effects and satisfaction were recorded at T3.SPSS 26.0 software package was used to analyze the data.RESULTS:Of the 90 patients,31 cases were included in CO group and 59 cases were included in Gl group.The average age of patients was 60.64 years and 70%were male.There was no significant difference in VAS and NRS at TO between GO group and G1 group(P>0.05).VAS and NRS at T1,T2 and T3 were significantly lower in G1 group compared to GO group(P<0.05).Patients in G1 group used significantly less analgesic medication(P<0.05),slept longer(P<0.05)and were more satisfied(P<0.05)than those in CO group at T3.CONCLUSIONS:EGFR-targeted therapy in combination with chemotherapy are more effective than chemotherapy alone in the alleviation of oral cancer pain and reduce the use of adjuvant analgesics.